Compare
Synlogic, Inc. vs Abbott Laboratories vs Bristol Myers Squibb Co vs Pfizer Inc
| Latest fiscal year | Synlogic, Inc. SYBX | Abbott Laboratories ABT | Bristol Myers Squibb Co BMY | Pfizer Inc PFE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $44.33B | $48.19B | $62.58B |
| Revenue growth (YoY) | -100.0% | +5.7% | -0.2% | -1.6% |
| Gross margin | n/a | 56.4% (computed) | n/a | 74.3% (computed) |
| Operating margin | n/a | 18.2% | n/a | n/a |
| Net margin | n/a | 14.7% | 14.6% | 12.4% |
| Net income | -$1.00M | $6.52B | $7.05B | $7.77B |
| EPS (Diluted) | -$0.08 | $3.72 | $3.46 | $1.36 |
| Operating cash flow | -$4.36M | $9.57B | $14.16B | $11.70B |
| Free cash flow | -$4.36M | $7.39B | $12.85B | $9.07B |
| Cash & equivalents | $14.67M | $8.52B | $10.21B | $1.14B |
| Total assets | $15.45M | $86.71B | $90.04B | $208.16B |
| Total liabilities | n/a | n/a | $71.53B | $121.39B |
| Shareholders' equity | $11.86M | $52.13B | $18.47B | $86.78B |
| Return on year-end equity | -8.5% | 12.5% | 38.2% | 9.0% |
| Shares outstanding | 11.70M | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Synlogic, Inc. | Abbott Laboratories | Bristol Myers Squibb Co | Pfizer Inc |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $44.33B Ended 2025-12-31 | $48.19B Ended 2025-12-31 | $62.58B Ended 2025-12-31 |
| 1 year earlier | $8.0K Ended 2024-12-31 | $41.95B Ended 2024-12-31 | $48.30B Ended 2024-12-31 | $63.63B Ended 2024-12-31 |
| 2 years earlier | $3.37M Ended 2023-12-31 | $40.11B Ended 2023-12-31 | $45.01B Ended 2023-12-31 | $59.55B Ended 2023-12-31 |
| 3 years earlier | $1.18M Ended 2022-12-31 | $43.65B Ended 2022-12-31 | $46.16B Ended 2022-12-31 | $101.17B Ended 2022-12-31 |
| 4 years earlier | $1.75M Ended 2021-12-31 | $43.08B Ended 2021-12-31 | $46.38B Ended 2021-12-31 | $81.29B Ended 2021-12-31 |